Eur Respir J 2004; 23:601-604
Copyright ©ERS Journals Ltd 2004
Influence of treatment on leptin levels in patients with obstructive sleep apnoea
B.M. Sanner1,2,
P. Kollhosser1,2,
N. Buechner1,
W. Zidek3 and
M. Tepel3
1 Dept of Medicine I, Ruhr University Bochum, Marienhospital Herne, Bochum, 2 Dept of Medicine, Bethesda Krankenhaus, Wuppertal, and 3 Dept of Medicine IV, Charite, Campus Benjamin Franklin, Berlin, Germany
CORRESPONDENCE: B.M. Sanner, Dept of Medicine, Bethesda Krankenhaus, Hainstr. 35, 42109 Wuppertal, Germany. Fax: 49 2022902005. E-mail: Bernd.Sanner@ruhr-uni-bochum.de
Keywords: leptin, obesity, sleep, sympathetic nervous system
Received: July 28, 2002
Accepted November 18, 2003
Obstructive sleep apnoea syndrome (OSAS) is a common disorder in obesity. Leptin, an adipocyte-derived signalling factor, plays an important role in metabolic control. There is growing evidence that leptin regulation is altered in OSAS. Therefore, the aim of this study was to test the hypothesis that effective treatment will influence leptin levels in OSAS patients.
Serum leptin levels were determined in 86 consecutive patients (aged 57.5±11.0 yrs) with polysomnographically verified OSAS. In addition, leptin levels were reassessed and treatment efficacy was evaluated by polysomnography after 6 months of therapy.
Patients were treated with continuous or bilevel positive airway pressure, a mandibular advancement device or conservatively, depending on the clinical symptoms. Mean serum leptin levels did not change with treatment in the whole study group (7.3±5.0 versus 7.5±4.8 ng·mL1), however, leptin levels decreased in effectively treated patients (8.5±5.0 versus 7.4±5.1 ng·mL1) while they increased in ineffectively treated patients (5.0±4.0 versus 7.7±4.1 ng·mL1). Furthermore, not only was there a significant and independent correlation between the change in leptin levels with treatment and the change in body mass index, but also with the change in apnoea/hypopnoea index.
Effective treatment of sleep-disordered breathing may have significant effects on leptin levels in obstructive sleep apnoea syndrome patients. Changes in leptin levels are related to changes in apnoea/hypopnoea index in obstructive sleep apnoea syndrome patients.
This article has been cited by other articles:

|
 |

|
 |
 
P. Levy, M. R. Bonsignore, and J. Eckel
Sleep, sleep-disordered breathing and metabolic consequences
Eur. Respir. J.,
July 1, 2009;
34(1):
243 - 260.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Tasali and M. S. M. Ip
Obstructive Sleep Apnea and Metabolic Syndrome: Alterations in Glucose Metabolism and Inflammation
Proceedings of the ATS,
February 15, 2008;
5(2):
207 - 217.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Pillar and N. Shehadeh
Abdominal Fat and Sleep Apnea: The chicken or the egg?
Diabetes Care,
February 1, 2008;
31(Supplement_2):
S303 - S309.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Hanaoka, X. Yu, K. Urushihata, M. Ota, K. Fujimoto, and K. Kubo
Leptin and Leptin Receptor Gene Polymorphisms in Obstructive Sleep Apnea Syndrome
Chest,
January 1, 2008;
133(1):
79 - 85.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Buyse and the participants of working group 2
Treatment effects of sleep apnoea: where are we now?
Eur. Respir. Rev.,
December 1, 2007;
16(106):
146 - 168.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. T. McNicholas
Cardiovascular outcomes of CPAP therapy in obstructive sleep apnea syndrome
Am J Physiol Regulatory Integrative Comp Physiol,
October 1, 2007;
293(4):
R1666 - R1670.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Campo, G. Fruhbeck, J. J. Zulueta, J. Iriarte, L. M. Seijo, A. B. Alcaide, J. B. Galdiz, and J. Salvador
Hyperleptinaemia, respiratory drive and hypercapnic response in obese patients
Eur. Respir. J.,
August 1, 2007;
30(2):
223 - 231.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. R. Chasens
Obstructive Sleep Apnea, Daytime Sleepiness, and Type 2 Diabetes
The Diabetes Educator,
May 1, 2007;
33(3):
475 - 482.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. T. McNicholas, M. R. Bonsignore, and the Management Committee of EU COST ACTION B26
Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities
Eur. Respir. J.,
January 1, 2007;
29(1):
156 - 178.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Spiegel, K. Knutson, R. Leproult, E. Tasali, and E. V. Cauter
Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes
J Appl Physiol,
November 1, 2005;
99(5):
2008 - 2019.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Barcelo, F. Barbe, E. Llompart, M. de la Pena, J. Duran-Cantolla, A. Ladaria, M. Bosch, L. Guerra, and A. G. N. Agusti
Neuropeptide Y and Leptin in Patients with Obstructive Sleep Apnea Syndrome: Role of Obesity
Am. J. Respir. Crit. Care Med.,
January 15, 2005;
171(2):
183 - 187.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by the European Respiratory Society.
|